Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 4
Submit an article Journal homepage
3,018
Views
8
CrossRef citations to date
0
Altmetric
Reports

Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry

Jart A. F. Oosterhavena Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The NetherlandsORCID Iconhttps://orcid.org/0000-0001-7214-7528
ORCID Icon,
Lotte S. Spekhorstb Department of Dermatology & Allergology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Junfen Zhanga Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Angelique N. Voorberga Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The NetherlandsORCID Iconhttps://orcid.org/0000-0001-5061-894X
ORCID Icon,
Geertruida L. E. Romeijna Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Celeste M. Boesjesb Department of Dermatology & Allergology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Marlies de Graafb Department of Dermatology & Allergology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Marjolein S. de Bruin-Wellerb Department of Dermatology & Allergology, University Medical Center Utrecht, Utrecht, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-1249-6993
ORCID Icon &
Marie L. A. Schuttelaara Department of Dermatology, University Medical Center Groningen, University of Groningen, Groningen, The NetherlandsCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0766-4382
ORCID Icon show all
Pages 1986-1989 | Received 03 Apr 2021, Accepted 17 May 2021, Published online: 21 Jun 2021

References

  • Silverberg JI. Atopic dermatitis in adults. Med Clin North Am. 2020;104(1):157–176.
  • Howells L, Thomas KS, Sears AV, Long-Term Control of Eczema Working Group for the HOME Initiative, et al. Defining and measuring 'eczema control': an international qualitative study to explore the views of those living with and treating atopic eczema. J Eur Acad Dermatol Venereol. 2019;33(6):1124–1132.
  • Howells L, Chalmers JR, Gran S, et al. Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: recap of atopic eczema (RECAP). Br J Dermatol. 2019;183(3):524–536.
  • Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin. 2019;36(3):367–376.
  • Simpson E, Eckert L, Gadkari A, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19(1):15.
  • Ariëns LFM, van der Schaft J, Bakker DS, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy. 2020;75(1):116–126.
  • Ariëns LF, van der Schaft J, Spekhorst LS, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-weeks results from the Dutch BioDay registry. J Am Acad Dermatol. 2020;84(4):1000–1009.
  • Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303.
  • Dupixent – summary of product characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent.
  • Castor EDC. Available from: https://www.castoredc.com.
  • Harmonizing Outcome Measures for Eczema (HOME). Available at: http://www.homeforeczema.org/index.aspx.
  • Tofte S. Eczema area and severity index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol. 1998;11:S197.
  • Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use . Clin Exp Dermatol. 1994;19(3):210–216.
  • Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–1519.
  • Atopic dermatitis control tool. Available from: https://www.adcontroltool.com/.
  • RECAP – The University of Nottingham. Available from: https://www.nottingham.ac.uk/research/groups/cebd/resources/recap.aspx.
  • Atkinson MJ, Kumar R, Cappelleri JC, et al. Hierarchical construct validity of the Treatment Satisfaction Questionnaire for Medication (TSQM Version II) among outpatient pharmacy consumers. Value Heal. 2005;8(SUPPL. 1):S9–S24.
  • Wei W, Ghorayeb E, Andria M, et al. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment. Ann Allergy, Asthma Immunol. 2019;123(4):381–388.e2.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.